Preoperative Intravitreal Conbercept Injection Reduced Both Angiogenic and Inflammatory Cytokines in Patients With Proliferative Diabetic Retinopathy.

To investigate the impact of intravitreal injection of conbercept, a recombinant fusion protein with decoy receptors for the vascular endothelial growth factor (VEGF) family, on intraocular concentrations of angiogenic and inflammatory mediators in patients with proliferative diabetic retinopathy (PDR), analyzed its potential impact on surgical outcomes. Forty eyes from 40 patients with PDR were included in this prospective study. Patients received intravitreal injection of conbercept followed by vitrectomy or phacovitrectomy in 1 week. Aqueous humor samples were collected before and 1 week after the conbercept injection. The concentrations of angiogenic and inflammatory cytokines and chemokines were measured by flow cytometry. Follow-up clinical data were collected and analyzed. Intravitreal conbercept injection significantly decreased aqueous concentrations of VEGF (325.5 (baseline) versus 22.3 pg/mL (postinjection), < 0.0001), PlGF (39.5 versus 24.5 pg/mL, < 0.0001), and PDGF-A (54.1 versus 47.0 pg/mL, = 0.0016), while no impact on bFGF levels. For inflammatory mediators, the concentration of TNF- (0.79 versus 0.45 pg/mL, = 0.0004) and IL-8 (180.6 versus 86 pg/mL, < 0.0001) were decreased, while IL-6 (184.1 versus 333.7 pg/mL, = 0.0003) and IL-10 (1.1 versus 1.5 pg/mL, = 0.0032) were increased. No significant changes in IFN- or MCP-1 were detected. Three months after surgery, the mean best-corrected visual acuity improved from a baseline of 1.8 ± 0.1 logMAR to 0.7 ± 0.1 logMAR ( < 0.0001), with 36 eyes (90%) achieving an improvement of visual function. Intravitreal conbercept injection presents dual effects of antiangiogenesis and anti-inflammation and can be served as an adjuvant treatment to vitrectomy for PDR patients.